课题基金 / 基金详情

CHEMICAL AND STRUCTURAL STUDIES ON FACTOR VIII/VON WILLEBRAND FACTOR PROTEIN

CHEMICAL AND STRUCTURAL STUDIES ON FACTOR VIII/VON WILLEBRAND FACTOR PROTEIN
因子 VIII/VON Willebrand 因子蛋白的化学和结构研究
批准号:
3939465
负责人:
H R GRALNICK
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

H R GRALNICK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long range purpose of this project initially is to study the immunologic aspects of the factor VIII/von Willebrand factor protein, and then to study the biochemistry and structure of this protein in man. The topics of present interest are: 1) the defect of the factor VIII/von Willebrand factor protein in hemophilia Ap; 2) the defect of the factor VIII/von Willebrand factor protein in von Willebrand's disease; 3) the importance of carbohydrate content in biological functions; 4) the relationship of carbohydrate content to atherosclerosis; 5) the mechanism of thrombin activation; and 6) biochemical characterization of the biologically active sites of the factor VIII/von Willebrand factor protein. Recent studies of the platelet von Willebrand factor isolated from human platelets reveal significant differences from its plasma counterpart. Studies of better purification methods will allow for greater yields which, in turn, will allow characterization of the platelet von Willebrand factor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INVESTIGATION OF HEMORRHAGIC AND THROMBOTIC DISORDERS IN MAN
  • 批准号:
    5201168
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H R GRALNICK
  • 依托单位:
THE USE OF DANAZOL IN THE TREATMENT OF HEMOPHILIA AND CHRISTMAS DISEASE
  • 批准号:
    4692040
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H R GRALNICK
  • 依托单位:
INVESTIGATION OF HEMORRHAGIC AND THROMBOTIC DISORDERS IN MAN
  • 批准号:
    4692027
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H R GRALNICK
  • 依托单位:
PLATELET STUDIES ON THE FLOW CYTOMETER
  • 批准号:
    3939471
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    H R GRALNICK
  • 依托单位:
海外基金